High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
about
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysisNeutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-AnalysisPrognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.Perioperative change in neutrophil-lymphocyte ratio predicts the overall survival of patients with bladder cancer undergoing radical cystectomy.Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
P2860
Q26773406-E21BC220-4F7E-4B41-A7C8-8977F3948B61Q28552296-F78408F1-3F09-4B3B-ABF2-B324B77EF452Q38623275-9CCB499C-9264-4D2D-8096-D767F091AEF5Q38811369-82DB9965-42EF-4B6B-A6D4-9110F1BA4093Q39031750-8891AED9-E839-4BEC-AFFE-A08DBA1F05CDQ39641273-0F298D9D-4535-43A4-9417-D75F0C647B3DQ40596744-716F6B82-4FB8-4B59-8140-6BF6672294F8Q41041538-1978D3FA-DF28-4313-B91A-74E89A5CAC0CQ48110694-8F8D8CB1-55ED-44CB-A7A2-9C6A1C52583FQ57074276-12287A41-FD57-4F3E-A8A0-A438EC2DA798
P2860
High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High neutrophil-to-lymphocyte ...... d with docetaxel chemotherapy.
@en
type
label
High neutrophil-to-lymphocyte ...... d with docetaxel chemotherapy.
@en
prefLabel
High neutrophil-to-lymphocyte ...... d with docetaxel chemotherapy.
@en
P2093
P2860
P356
P1476
High neutrophil-to-lymphocyte ...... d with docetaxel chemotherapy.
@en
P2093
Akihisa Yao
Atsushi Takenaka
Hideto Iwamoto
Masashi Honda
Shuichi Morizane
Takehiro Sejima
Toshihiko Masago
P2860
P304
P356
10.1111/IJU.12839
P577
2015-06-18T00:00:00Z